^
Association details:
| Biomarker: | BRAF V600E + MSI-H |
|---|---|
| Cancer: | Colorectal Cancer |
| Regimen: | (Avastin (bevacizumab) + capecitabine + oxaliplatin) (capecitabine + oxaliplatin) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Cutaneous metastasis of cecum cancer with MSI-high and BRAFV600E mutation: a case report
Published date:
08/18/2021
Excerpt:
The expression of KRAS wild type, BRAFV600E mutation, and MSI-high was detected in the cecum cancer using molecular pathological examination. She received chemotherapy with XELOX + BEV regimen (capecitabine + oxaliplatin + bevacizumab). After four administrations, a computed tomography scan showed reduction of distant metastases, which suggested partial response,
Secondary therapy:
Chemotherapy
DOI:
10.1186/s40792-021-01265-w
